share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股sec公告 ·  04/26 16:18
Moomoo AI 已提取核心訊息
On April 24, 2024, bluebird bio, Inc. received a notice from The Nasdaq Stock Market LLC indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023. The company has until June 24, 2024, to submit a plan to regain compliance and may be granted an extension until October 14, 2024, to file the report. The delay is attributed to the need to restate financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of 2023 and 2022. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements, which are not expected to impact...Show More
On April 24, 2024, bluebird bio, Inc. received a notice from The Nasdaq Stock Market LLC indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023. The company has until June 24, 2024, to submit a plan to regain compliance and may be granted an extension until October 14, 2024, to file the report. The delay is attributed to the need to restate financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of 2023 and 2022. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements, which are not expected to impact the company's cash position or revenue. bluebird bio intends to submit a compliance plan before the deadline and file the 2023 Form 10-K as soon as possible. The company issued a press release on April 26, 2024, to announce the receipt of the Nasdaq notice. The notice does not immediately affect the listing of the company's securities on Nasdaq.
2024年4月24日,藍鳥生物公司收到納斯達克股票市場有限責任公司的通知,表明由於延遲提交截至2023年12月31日止年度的10-K表年度報告,該公司未遵守納斯達克上市規則5250(c)(1)。該公司必須在2024年6月24日之前提交恢復合規的計劃,並可能獲准將提交報告的期限延長至2024年10月14日。延遲歸因於需要重報截至2022年12月31日的年度的財務報表,以及2023年和2022年前三個季度的未經審計的財務信息。重報與嵌入式租賃的確定和租賃協議中非租賃部分的處理有關,預計不會影響公司的現金狀況或收入。bluebird bio打算在截止日期之前提交合規計劃,並儘快提交2023年10-K表格。該公司於2024年4月26日發佈了一份新聞稿,宣佈收到納斯達克的通知。該通知並未立即影響該公司證券在納斯達克的上市。
2024年4月24日,藍鳥生物公司收到納斯達克股票市場有限責任公司的通知,表明由於延遲提交截至2023年12月31日止年度的10-K表年度報告,該公司未遵守納斯達克上市規則5250(c)(1)。該公司必須在2024年6月24日之前提交恢復合規的計劃,並可能獲准將提交報告的期限延長至2024年10月14日。延遲歸因於需要重報截至2022年12月31日的年度的財務報表,以及2023年和2022年前三個季度的未經審計的財務信息。重報與嵌入式租賃的確定和租賃協議中非租賃部分的處理有關,預計不會影響公司的現金狀況或收入。bluebird bio打算在截止日期之前提交合規計劃,並儘快提交2023年10-K表格。該公司於2024年4月26日發佈了一份新聞稿,宣佈收到納斯達克的通知。該通知並未立即影響該公司證券在納斯達克的上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息